COMMUNIQUÉS West-GlobeNewswire

CBDrmd.com Launches CBD Gummies and CBD Oil Transparency Initiative
02/07/2026
New educational resource helps adults better understand CBD gummies, CBD oil, product labels, lab reports, ingredient disclosures, THC information, refund policies, and responsible CBD product research. NEW YORK,USA, [...]
Cosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases
02/07/2026
CHICAGO, July 02, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an [...]
GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
02/07/2026
Coverage and future reimbursement ( effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered by GENFIT’s proprietary NIS4® technology Focuses on patients at highest [...]
Declaration voting rights - June 30,2026
02/07/2026
VALNEVA Declaration of shares and voting rights Status as of June 30, 2026 __________________________________________________________________________________________ Company name: VALNEVA Registered office: Îlot Saint- [...]
SRX Global Makes Strategic Investment in Critical and Precious Minerals Development Company, Greenland Mines
02/07/2026
NORTH PALM BEACH, Fla., July 02, 2026 (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE American: SRXH) (the "Company", or “SRX”), an AI-enabled platform dedicated to generating returns across high-conviction operating [...]
Déclaration droits de vote - 30 juin 2026
02/07/2026
VALNEVA Déclaration d’actions et de droits de vote Statut au 30 juin 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social [...]
GENFIT annonce l’accès à la couverture et le futur remboursement par Medicare aux États-Unis de NASHnext®, une technologie visant à identifier les patients atteints de MASH « à risque »
02/07/2026
Couverture et futur remboursement sécurisés pour NASHnext®, le test diagnostique sanguin non invasif développé par Labcorp, basé sur la technologie propriétaire NIS4® de GENFIT Un ciblage sur les patients les plus à [...]
Profusa Announces 1-for-25 Reverse Stock Split
02/07/2026
BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the [...]
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
02/07/2026
Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN [...]
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
02/07/2026
Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic [...]
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
02/07/2026
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical [...]
Zelluna ASA - Grant of Share Options
02/07/2026
Oslo, 2 July 2026: On the basis of the authorization granted by the General Meeting on 23 April 2026 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to employees and board [...]
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions
02/07/2026
SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
02/07/2026
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Cannabix Technologies Announces Detection of Methamphetamine and Amphetamine in Human Breath
02/07/2026
Methamphetamine & Amphetamine Detection in Breath Represents a Significant New Opportunity for Cannabix Technologies Inc. VANCOUVER, British Columbia, July 02, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. ( [...]
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
02/07/2026
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech’s CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - Demonstrates [...]
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
02/07/2026
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and [...]
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
02/07/2026
The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period MELBOURNE, Australia, July 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a [...]

Pages